CA
NZ
UK
AU
IND
US
…
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Structure Therapeutics is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that modulate G protein–coupled receptors (GPCRs) using structure-based drug discovery technology. Long-term growth may be driven by clinical progress across its pipeline, the ability of its discovery platform to generate additional candidates, and potential partnerships or licensing that could support development and commercialization, which may attract investors seeking exposure to GPCR-targeted therapeutics. Material risks include clinical trial failures and regulatory setbacks, high capital needs with potential dilution, and strong competition in GPCR-focused therapeutic areas.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -140.69M | -122.22M | -89.38M | -51.30M | -0.04M |
| Minority interest | - | - | - | 0.00M | - |
| Net income | -141.20M | -122.53M | -89.62M | -51.32M | -0.04M |
| Selling general administrative | 61.55M | 49.41M | 32.67M | 16.37M | 0.01M |
| Selling and marketing expenses | - | - | 0.00M | - | - |
| Gross profit | -3.90M | -2.60M | -0.95M | - | - |
| Reconciled depreciation | 1.33M | 0.99M | 0.29M | 0.28M | 0.00M |
| Ebit | -140.69M | -158.23M | -102.78M | -52.84M | -0.04M |
| Ebitda | -136.79M | -157.24M | -102.48M | -52.56M | -0.04M |
| Depreciation and amortization | 3.90M | 0.99M | 0.29M | 0.28M | 0.00M |
| Operating income | -287.57M | -158.23M | -102.78M | -52.56M | -0.04M |
| Other operating expenses | 287.57M | 158.23M | 102.78M | 52.56M | 0.04M |
| Interest expense | - | - | 13.39M | -1.53M | 0.01M |
| Tax provision | 0.52M | 0.31M | 0.24M | 0.02M | 0.00M |
| Net interest income | 35.87M | 36.01M | 13.39M | 1.26M | -0.00M |
| Income tax expense | 0.52M | 0.31M | 0.24M | 0.02M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 283.67M | 158.23M | 102.78M | 52.56M | 0.04M |
| Cost of revenue | 3.90M | 2.60M | 0.95M | - | - |
| Total other income expense net | 146.51M | 36.01M | 13.39M | 1.26M | -0.00M |
| Net income from continuing ops | -141.20M | -122.53M | -89.62M | -51.32M | -0.04M |
| Net income applicable to common shares | - | - | - | - | -43.77M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1583.92M | 903.33M | 482.02M | 97.84M | 0.11M |
| Other current assets | 124.11M | 7.69M | 6.29M | 2.25M | 1.94M |
| Total liab | 67.54M | 38.49M | 29.05M | 212.99M | 0.18M |
| Total stockholder equity | 1516.38M | 864.84M | 452.97M | -115.14M | -0.06M |
| Deferred long term liab | - | - | - | 3.40M | 0.10M |
| Other current liab | 46.54M | 26.30M | 18.20M | 6.74M | -3.48M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.00M | 0.00M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.00M | 0.00M |
| Retained earnings | -470.30M | -329.10M | -206.57M | -116.95M | -0.06M |
| Other assets | - | - | 0.00M | 3.46M | 0.11M |
| Cash | 799.62M | 169.51M | 129.79M | 90.84M | 0.11M |
| Total current liabilities | 63.28M | 36.02M | 24.74M | 13.01M | 0.01M |
| Current deferred revenue | - | - | 0.36M | - | - |
| Net debt | -793.14M | -165.65M | -124.34M | -90.58M | -0.10M |
| Short term debt | 2.88M | 1.70M | 1.44M | 0.26M | 0.00M |
| Short long term debt total | 6.49M | 3.86M | 5.45M | 0.26M | 0.00M |
| Other stockholder equity | 1985.60M | 1193.01M | 659.00M | -131.09M | - |
| Property plant equipment | - | - | - | 1.29M | 1.79M |
| Total current assets | 1570.30M | 891.21M | 473.61M | 93.09M | 0.11M |
| Net tangible assets | - | - | - | -115.14M | -64.73M |
| Short term investments | 646.57M | 714.01M | 337.53M | 64.75M | 0.00M |
| Accounts payable | 13.86M | 8.02M | 4.74M | 6.01M | 3.48M |
| Accumulated other comprehensive income | 1.05M | 0.91M | 0.52M | -0.11M | - |
| Non currrent assets other | 0.72M | 5.11M | 0.04M | 3.46M | 0.00M |
| Non current assets total | 13.62M | 12.12M | 8.41M | 4.76M | 0.00M |
| Capital lease obligations | 6.49M | 3.86M | 5.45M | 0.26M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 93.41M | -358.91M | -268.34M | -62.11M | 0.02M |
| Change to liabilities | - | - | - | 2.15M | 1.90M |
| Total cashflows from investing activities | 89.80M | -358.91M | -268.34M | -62.11M | 17.86M |
| Total cash from financing activities | 762.52M | 515.26M | 451.53M | 29.01M | 0.10M |
| Change to operating activities | - | - | - | 0.81M | 2.17M |
| Net income | -141.20M | -122.53M | -89.62M | -51.32M | -0.04M |
| Change in cash | 630.12M | 39.72M | 103.70M | -79.21M | 0.09M |
| Begin period cash flow | 169.51M | 129.79M | 26.09M | 105.31M | 0.02M |
| End period cash flow | 799.63M | 169.51M | 129.79M | 26.09M | 0.11M |
| Total cash from operating activities | -222.20M | -116.64M | -79.49M | -46.12M | -0.03M |
| Issuance of capital stock | 665.71M | 514.57M | 472.30M | 31.50M | 0.10M |
| Depreciation | 1.33M | 0.99M | 0.29M | 0.28M | 0.00M |
| Other cashflows from investing activities | 10.25M | -357.62M | -0.23M | - | - |
| Other cashflows from financing activities | -4.66M | 0.69M | -20.77M | 29.01M | 0.10M |
| Change to netincome | - | - | - | 1.96M | 1.71M |
| Capital expenditures | 3.61M | 1.29M | 2.17M | 0.15M | 0.00M |
| Change in working capital | -88.27M | 2.96M | 6.97M | 2.97M | 0.00M |
| Stock based compensation | 28.99M | 18.79M | 8.19M | 2.51M | 0.00M |
| Other non cash items | -23.05M | -16.86M | -5.32M | -0.56M | 0.00M |
| Free cash flow | -225.81M | -117.93M | -81.66M | -46.27M | -0.03M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics Inc. American Depositary Shares |
-0.07 0.32% |
21.87 | - | - | - | 2.02 | -13.46 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
601 Gateway Boulevard, South San Francisco, CA, United States, 94080
650 457 1978
281
| Name | Title | Year Born |
|---|---|---|
| Dr. Raymond C. Stevens Ph.D. | CEO & Director | 1964 |
| Dr. Yingli Ma Ph.D. | Chief Technology Officer | 1974 |
| Dr. Mark A. Bach M.D., Ph.D. | Chief Medical Officer | 1957 |
| Mr. Jun S. Yoon | Co- Founder, CFO & Secretary | 1978 |
| Dr. Xichen Lin Ph.D. | Chief Scientific Officer | 1974 |
| Mr. Tony Peng | Senior Vice President of Legal | NA |
| Mr. Bob Gatmaitan | Senior Vice President of People | NA |
| Dr. Hui Lei Ph.D. | Senior Vice President of Chemistry | NA |
| Dr. Fang Zhang Ph.D. | Executive VP & Head of Biology | NA |
| Ms. Lani Ibarra | Senior Vice President of Clinical Development Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...